Paul Farrant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul Farrant has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Andrew Carmichael
The James Cook University Hospital, Middlesbrough, UK
1 shared publicationC. Degiovanni
Dermatology Department, Brighton General Hospital, Brighton, UK
1 shared publicationCharles Darley
Brighton General Hospital, Brighton, UK
1 shared publicationD. McGibbon
St John's Institute of Dermatology, St Thomas' Hospital, London, UK
1 shared publicationJ. Hextall
Department of Dermatology, Worthing Hospital, West Sussex, UK
1 shared publicationM. Gore
Department of Dermatology, St George's Hospital, Cancer Medicine, The Royal Marsden Hospital, London, UK
1 shared publication
Latest Publications
- 1 June 2009
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 34 (4) , 549-551
Tender erythematous nodules on the lower limb
- 1 June 2009
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 34 (4) , 549-551
Tender erythematous nodules on the lower limb
- 1 April 2009
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 34 (3) , 435-436
Familial yellow papules
- 1 April 2009
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 34 (3) , 435-436
Familial yellow papules
- 1 July 2008
- Published by Wiley in Pediatric Dermatology
- Vol. 25 (4) , 479-482
Is Erythromycin an Effective Treatment for Chronic Bullous Disease of Childhood? A National Survey of Members of the British Society for Paediatric Dermatology
Abstract: Chronic bullous disease of childhood is the commonest acquired blistering disorder of children. Erythromycin has been reported to be beneficial for this condition. A three question survey was e‐mailed to all members of the British Society for Paediatric Dermatology to assess the incidence, preferred treatments and experience of oral erythromycin in treating chronic bullous disease of childhood. A second, more detailed questionnaire was sent to members who had used erythromycin. Forty patients were reported to have been treated over the previous 2 years. The preferred treatment was dapsone. Erythromycin alone had been used in five children as first‐line oral treatment. In three of these patients the initial improvement was graded as either “good” or “complete resolution.” This benefit was only sustained in one child, with the other two relapsing between 4 and 12 weeks. In a further eight children, erythromycin had been used with other oral agents. In five of these children, erythromycin was associated with long‐term benefit. These results suggest that erythromycin is unlikely to produce sustained improvement in chronic bullous disease of childhood when used as a sole first‐line agent. However, erythromycin can cause an initial improvement, which may be useful whilst awaiting results of diagnostic tests and may confer benefit when used with other systemic treatments.
- 1 July 2008
- Published by Wiley in Pediatric Dermatology
- Vol. 25 (4) , 479-482
Is Erythromycin an Effective Treatment for Chronic Bullous Disease of Childhood? A National Survey of Members of the British Society for Paediatric Dermatology
Abstract: Chronic bullous disease of childhood is the commonest acquired blistering disorder of children. Erythromycin has been reported to be beneficial for this condition. A three question survey was e‐mailed to all members of the British Society for Paediatric Dermatology to assess the incidence, preferred treatments and experience of oral erythromycin in treating chronic bullous disease of childhood. A second, more detailed questionnaire was sent to members who had used erythromycin. Forty patients were reported to have been treated over the previous 2 years. The preferred treatment was dapsone. Erythromycin alone had been used in five children as first‐line oral treatment. In three of these patients the initial improvement was graded as either “good” or “complete resolution.” This benefit was only sustained in one child, with the other two relapsing between 4 and 12 weeks. In a further eight children, erythromycin had been used with other oral agents. In five of these children, erythromycin was associated with long‐term benefit. These results suggest that erythromycin is unlikely to produce sustained improvement in chronic bullous disease of childhood when used as a sole first‐line agent. However, erythromycin can cause an initial improvement, which may be useful whilst awaiting results of diagnostic tests and may confer benefit when used with other systemic treatments.
- 1 September 2004
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 29 (5) , 569-570
Hand graft or hard luck
- 1 September 2004
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 29 (5) , 569-570
Hand graft or hard luck
- 1 July 2004
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 29 (4) , 360-362
Scleroderma and the taxanes. Is there really a link?
Scleroderma has been associated with exposure to many substances in the past ranging from vinyl chloride to silicon dioxide. In recent years there have been a number of case reports linking modern chemotherapy agents, such as the taxanes to the development of scleroderma like changes. We present a further case of scleroderma in association with chemotherapy but question the role of some of the agents previously implicated. A brief review of the current literature is included.
- 1 July 2004
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 29 (4) , 360-362
Scleroderma and the taxanes. Is there really a link?
Scleroderma has been associated with exposure to many substances in the past ranging from vinyl chloride to silicon dioxide. In recent years there have been a number of case reports linking modern chemotherapy agents, such as the taxanes to the development of scleroderma like changes. We present a further case of scleroderma in association with chemotherapy but question the role of some of the agents previously implicated. A brief review of the current literature is included.